Protocol Title: A Phase 1b, Open-label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of NKTR-214 in Combination with Anti-PD-1 (Pembrolizumab) or Anti-PD-L1 (Atezolizumab) in Patients with Locally Advanced or Metastatic Solid Tumors

Target Population: Locally Advanced or Metastatic Solid Tumors, including Non-Small Cell Lung Cancer (NSCLC), Urinary Bladder Neoplasms, or Melanoma

Summary: This study is to assess the safety and tolerability, define the maximum tolerated dose (MTD) or recommended Phase 2 dose and to assess the preliminary clinical benefit of NKTR-214 when combined with Pembrolizumab or Atezolizumab.

Key Eligibility Criteria:
- Histologically confirmed locally advanced/metastatic Melanoma or Urothelial Carcinoma, or metastatic NSCLC.
- Life expectancy > 12 Weeks as determined by the Investigator.
- ECOG Performance Status 0 or 1.
- Must have Measurable disease.
- Patients must NOT have received prior oncology regimens, including but not limited to inhibitors such as anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T cell co stimulation or checkpoint pathways, indoleamine 2,3-dioxygenase pathway inhibitors, cancer vaccines, adoptive cell therapies, or other cytokine therapies.

- **MELANOMA Cohort:**
  - Histologically confirmed or cytologically confirmed diagnosis of Stage IV NSCLC.
  - First-line (Pembrolizumab only), patients must have high PD-L1 expression ([TPS] ≥ 50%), with no EGFR or ALK genomic tumor aberrations.
  - Second-line (Pembrolizumab or Atezolizumab), patients must have experienced disease recurrence or progression during or after a prior platinum-based chemotherapy given for advanced or metastatic disease.
    - Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations and must not have received chemotherapy.

- **NON-SMALL CELL LUNG CANCER (NSCLC) Cohort:**
  - Histologically confirmed or cytologically confirmed locally advanced or metastatic Urothelial Carcinoma.
  - First-line (Pembrolizumab only), patients who are not eligible for Cisplatin-containing chemotherapy.
  - First-line (Atezolizumab only), patients who have disease progression within 12 Months of neoadjuvant or adjuvant treatment with chemotherapy.
  - Second-line (Pembrolizumab or Atezolizumab), patients who have disease progression during or following platinum-containing chemotherapy.

Contacts:
- **Principal Investigator:** Marc Matrana, MD
- **Research Nurses (RN):** Amanda Woolery (amanda.woolery@ochsner.org, ext. 20275)
  Sharon Jerdonek (sharon.jerdonek@ochsner.org, ext. 23929)

For additional information: [https://clinicaltrials.gov/ct2/show/NCT03138889](https://clinicaltrials.gov/ct2/show/NCT03138889)